POINT: Prosthesis–patient mismatch does not affect survival for patients greater than 70 years of age undergoing bioprosthetic aortic valve replacement  by Moon, Marc R. et al.
POINT/COUNTERPOINTPoint/Counterpoint Moon et alPOINT: Prosthesis–patient mismatch does not affect survival for patients
greater than 70 years of age undergoing bioprosthetic aortic valve
replacement
Marc R. Moon, MD, Jennifer S. Lawton, MD, Nader Moazami, MD, Nabil A. Munfakh, MD, Michael K. Pasque, MD, and
Ralph J. Damiano, Jr, MD
Objective: The purpose of this investigation was to examine the impact of prosthesis–patient mismatch after bio-
prosthetic aortic valve replacement on long-term survival in patients greater than 70 years of age compared with
those less than or equal to 70 years of age.
Methods: Between 1992 and 2007, 1399 patients underwent bioprosthetic aortic valve replacement, including
881 (63%) patients older than 70 years of age. Prosthesis–patient mismatch was defined as severe (prosthetic ef-
fective orifice area/body surface area<0.65 cm2/m2), moderate (0.65–0.85 cm2/m2), or absent (>0.85 cm2/m2).
For patients less than or equal to 70 years of age, mismatch was severe in 62 (12%), moderate in 251 (48%), and
absent in 205 (40%). For patients greater than 70 years of age, mismatch was severe in 109 (12%), moderate in
451 (51%), and absent in 321 (37%). There was no difference in the distribution of prosthesis–patient mismatch
between age groups (P ¼ .50).
Results: For patients less than or equal to 70 years, prosthesis–patient mismatch was associated with impaired
long-term survival (P ¼ .02). Survival at 5 and 10 years was 61% 7% and 28%  12% for severe mismatch,
65%  3% and 40%  5% for moderate mismatch, and 73%  5% and 46%  9% for no mismatch. For
patients greater than 70 years, prosthesis–patient mismatch did not affect long-term survival (P ¼ .25). Survival
at 5 and 10 years was 62% 5% and 42% 6% for severe mismatch, 62% 2% and 30% 5% for moderate
mismatch, and 53%  4% and 29%  5% for absent mismatch.
Conclusions:After bioprosthetic aortic valve replacement, prosthesis–patient mismatch had a negative impact on
late survival for patients less than or equal to 70 years of age, but for patients greater than 70 years of age, pros-
thesis–patient mismatch did not influence late survival.See related article on page 284.
When aortic valve replacement (AVR) is being performed, it
is generally accepted that putting a small valve into a large
patient is suboptimal, but the degree to which prosthesis–
patient mismatch (PPM) affects outcome in specific patient
subgroups remains unclear. A handful of studies suggest
that increased transvalvular gradients negatively affect left
ventricular (LV) mass regression and long-term out-
comes,1-4 whereas other large, multicenter studies demon-
strate no impact of PPM on long-term survival.5-7 The
magnitude to which varying degrees of PPM affect early
and late survival may depend on specific patient characteris-
tics in addition to the ratio of valve to body size.2,3,8-10 In
a previous report from our institution, multivariate analysis
of patients undergoing AVR (mechanical or bioprosthetic)
identified age and body surface area as important factors
when evaluating the impact of PPM,8 whereas a recent study
from Reul and colleagues9 documented the importance of
LV dysfunction on outcomes with PPM. The purpose of
the current investigation was to focus on patients undergoing
bioprosthetic AVR to determine the impact of PPM on long-
term survival in young patients versus older patients. Our
hypothesis was that the impact of PPM on long-term out-
come would be related to patient age, with younger patients
more likely to have a negative impact from PPM.
PATIENTS AND METHODS
During a 15-year period (June 1992 to July 2007), 2085 patients under-
went AVR at Washington University School of Medicine (Barnes–Jewish
Hospital and Christian Hospital Northeast) by 22 different surgeons. Of
these, 1399 (67%) underwent bioprosthetic AVR and are the subject of
this analysis. Figure 1 demonstrates a shift toward bioprosthetic prostheses
in the later years of the study. There were 818 (58%) men and 581 (42%)
women with a mean age (1 standard deviation) of 71  13 years (range,
19–95 years). Of these biosprosthesis recipients, 1187 (85%) were greater
than 60 years of age, 881 (63%) were greater than 70 years of age, and 321
(23%) were greater than 80 years of age. Indications for AVR included ste-
nosis (59%), regurgitation (13%), combined stenosis and regurgitation
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(19%), and endocarditis (9%). A total of 60 (4%) patients previously un-
derwent AVR and 154 (11%) previously underwent coronary artery bypass
grafting. Concomitant coronary artery bypass grafting was performed in 643
(46%) patients with an average of 2.2  1.1 grafts, and concomitant mitral
valve repair or replacement was performed in 149 (11%) patients (64 repair,
85 replacement).
Ideally, the actual effective orifice area (EOA) would have been deter-
mined for each patient’s prosthesis, but postoperative echocardiography
was inconsistent throughout this retrospective series. Thus, estimated pros-
thetic EOA for each valve type and size was obtained from referenced nor-
mal valves.8,11,12 Mean body surface area (BSA) was 1.93  0.26 m2.
Indexed EOA was defined as prosthetic EOA divided by BSA, and PPM
was defined as severe (EOA/BSA< 0.65 cm2/m2), moderate (EOA/BSA
between 0.65 cm2/m2 and 0.85 cm2/m2), or absent (EOA/BSA> 0.85
cm2/m2).
Survival data were obtained for all patients during a 2-month closing in-
terval ending September 2007 through interrogation of the Barnes–Jewish
Hospital medical records database and the Social Security Death Index. Cu-
mulative long-term follow-up totaled 5331 patient-years. Mean follow-up
for all patients was 46  40 months, and 813 (58%) patients were alive
an average of 53  39 months postoperatively. This study was approved
by the Washington University School of Medicine Institutional Review
Board, and informed consent and permission for release of information
were obtained.
Data Analysis
Operative mortality included any death that occurred during the initial
hospitalization or within 30 days of operation for discharged patients.
Late survival data included death from all causes. Continuous data are re-
ported as mean  1 standard deviation and were compared between groups
by analysis of variance. Clinically important ratios are reported with 95%
confidence limits. Actuarial survival estimates were calculated by the Ka-
plan–Meier method and were compared by the log–rank test. Variability
of the actuarial estimates is expressed as  1 standard error of the mean.
Multivariate analysis (stepwise backward regression) was used to determine
the preoperative and intraoperative risk factors that were significant, inde-
pendent predictors of PPM and death (SigmaStat 2.03; SPSS Inc, Chicago,
Ill). Odds ratios (OR) are reported with 95% confidence intervals (CI), and
regression coefficients for continuous variables are reported with standard
error of the mean. Twenty-three variables were analyzed: age, year of oper-
ation, gender, hypertension, diabetes, pulmonary disease, cerebrovascular
disease, peripheral vascular disease, chronic renal insufficiency, history of
myocardial infarction, smoking history, congestive heart failure, ejection
fraction, status (urgent, elective), ascending aortic aneurysm, endocarditis,
New York Heart Association class, LV dysfunction (ejection fraction<
0.40), previous cardiac operation, concomitant coronary artery bypass graft-
ing, concomitant mitral repair or replacement, BSA, and degree of PPM. We
did not believe that it was important to specifically analyze the impact of the
brand of valve implanted or prosthesis size on the incidence of PPM inas-
much as this would have represented a circular argument hampered by
selection bias.
RESULTS
Patient Characteristics
For patients less than or equal to 70 years of age, PPM was
severe in 62 (12%), moderate in 251 (48%), and absent in
205 (40%). For patients greater than 70 years of age, PPM
was severe in 109 (12%), moderate in 451 (51%), and ab-
sent in 321 (37%). There was no difference in the distribu-
tion of PPM between age groups (P ¼ .50). Important
preoperative patient characteristics are summarized in Table
1. Multivariate analysis identified 5 factors to be indepen-
dent predictors of severe PPM: (1) earlier operative year
(P< .001, coefficient ¼ 0.011  0.002), (2) increased
BSA (P< .001, 0.274  0.033), (3) female gender (P<
.001, OR ¼ 2.4 [95% CI, 1.7–3.3]), (4) diabetes mellitus
(P<.001, 2.7 [1.9–3.7]), and (5) emergency or urgent status
(P ¼ .01, 1.8 [1.2–2.8]). Severe or moderate PPM was less
common in later years, potentially owing to the introduction
of bioprostheses with a higher EOA or a change in surgical
technique (Figure 2).
Operative Mortality
Operative mortality was 9% 1% overall (124/1399 pa-
tients), but increased as the complexity of the procedure in-
creased from 4% for an elective, nonendocarditis AVR to
20% to 22% for an AVR combined with a mitral valve pro-
cedure (Table 2). Operative mortality was 7% 2% for pa-
tients less than or equal to 70 years of age (38/518) and 10%
 2% for patients greater than 70 years (86/881) (P ¼ .15).
For patients less than or equal to 70 years of age, operative
mortality tended to be higher with severe PPM (13% 8%)
FIGURE 1. Numbers of bioprosthetic (solid circles) and mechanical (open
circles) prostheses implanted in the aortic position between 1992 and 2007.
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but the difference did not reach statistical significance (P ¼
.20). For patients greater than 70 years of age, there was
no difference in operative mortality with severe PPM
(10%  6%), moderate PPM (9%  3%), or no PPM
(11%  3%) (P ¼ .49). Multivariate analysis identified 5
factors to be independent predictors of operative mortality:
(1) chronic renal insufficiency (P< .001, OR ¼ 4.2 [95%
CI, 2.8–6.5]), (2) peripheral vascular disease (P ¼ .002,
2.3 [1.5–3.5]), (3) congestive heart failure (P< .001, 3.6
[2.2–6.0]), (4) simultaneous mitral valve procedure (P<
.001, 3.4 [2.2–5.4]), and (5) emergency or urgent status
(P< .001, 3.8 [2.4–6.1]).
Late Survival
Among the 1275 operative survivors, there were 586 late
deaths. For all patients, PPM was not associated with im-
paired long-term survival (P ¼ .65). Survival at 5 and 10
years was 61%  4% and 40%  6% for severe PPM
(mean survival 92 months), 63%  33% and 33%  3%
for moderate PPM (90 months), and 60%  3% and 35%
 5% for no PPM (86 months) (Figure 3). To exclude pa-
tients with limited expected survival, survival analyses
were repeated including only patients who survived greater
than 12 months. Similarly, late survival was independent of
the degree of PPM (10-year survival: 51%  7% severe
PPM, 40%  3% moderate PPM, and 42%  6% no
PPM; P ¼ .30). Multivariate analysis identified 7 factors
to be independent predictors of late death: (1) diabetes mel-
litus (P< .001, OR ¼ 1.4 [95% CI, 1.1–1.8]), (2) chronic
renal insufficiency (P< .001, 3.6 [2.5–5.2]), (3) peripheral
vascular disease (P< .001, 1.8 [1.3–2.4]), (4) New York
Heart Association class IV (P< .001, 1.5 [1.1–1.8]), (5)
simultaneous mitral valve procedure (P ¼ .002, 2.1 [1.5–
3.0]), (6) advanced age (P ¼ .002, coefficient ¼ 0.006 
0.001), and (7) earlier operative year (P< .001, 0.054
 0.002).
For patients less than or equal to 70 years of age, PPM was
associated with impaired long-term survival (P ¼ .02). Sur-
vival at 5 and 10 years was 61% 7% and 28% 12% for
severe PPM (mean survival 77 months), 65%  3% and
40%  5% for moderate PPM (92 months), and 73% 
5% and 46%  9% for no PPM (98 months) (Figure 4).
To determine whether higher levels of acuity were responsi-
ble for the difference in younger patients, we compared sur-
vivals between PPM groups excluding patients with
endocarditis and emergency or urgent surgery. Similarly,
for younger patients, PPM was associated with impaired
TABLE 1. Patient characteristics
No PPM Moderate PPM Severe PPM P value
No. of patients 526 702 171
Age (y) 70  13 72  12 71  12 ¼ .07
Patients greater than 70 y 321 (61%) 451 (64%) 109 (64%) ¼ .50
BSA (m2) 1.87  0.25 1.94  0.25 2.09  0.26 < .001
Female gender 214 (41%) 264 (38%) 103 (60%) < .001
Diabetes mellitus 128 (24%) 174 (25%) 80 (47%) < .001
Emergency/urgent status 43 (8%) 89 (13%) 31 (18%) < .001
PPM, Prosthesis–patient mismatch; BSA, body surface area. Continuous variables are mean  standard deviation. Groups were compared using analysis of variance or c2 test as
appropriate. P values refer to the comparison among all three groups.
FIGURE 2. Impact of operative year on the incidence of severe and mod-
erate prosthesis–patient mismatch (PPM) during bioprosthetic aortic valve
replacement.
TABLE 2. Operative mortality based on the complexity of the
operation
AVR only 6%  2% (40/661)
AVR only: elective 5%  2% (28/610)
AVR only: elective, nonendocarditis 4%  2% (25/566)
AVR, CABG 9%  2% (52/589)
AVR, MVR 22%  8% (21/95)
AVR, MVR, CABG 20%  11% (11/54)
AVR, Aortic valve replacement; MVR, mitral valve replacement; CABG, coronary
artery bypass grafting.
280 The Journal of Thoracic and Cardiovascular Surgery c February 2009
Moon et al Point/Counterpointlong-term survival in elective, nonendocarditis patients (10-
year survival: 22%  12% severe PPM, 39%  6% mod-
erate PPM, and 47%  10%, no PPM; P ¼ .009).
For patients greater than 70 years of age, PPM did not af-
fect long-term survival (P¼ .25). Survival at 5 and 10 years
was 62% 5% and 42% 6% for severe PPM (mean sur-
vival 96 months), 62% 2% and 30% 5% for moderate
PPM (87 months), and 53%  4% and 29%  5% for ab-
sent PPM (77 months) (Figure 5). Similarly, when excluding
endocarditis and emergency or urgent indications for sur-
gery, long-term survival was independent of PPM in older
patients (10-year survival: 43%  7% severe PPM, 30%
 4% moderate PPM, and 29%  6%, no PPM; P ¼ .28).
To determine whether a different cutoff age would yield
dissimilar results with regard to the impact of PPM on sur-
vival, we repeated analyses with cutoff ages of 60 years
FIGURE 3. Impact of prosthesis–patient mismatch (PPM) on late survival
for all patients undergoing bioprosthetic aortic valve replacement. The num-
bers of patients at risk for each mismatch group are reported at 0, 2, 4, 6, 8,
and 10 years.
FIGURE 4. Impact of prosthesis–patient mismatch (PPM) on late survival
after bioprosthetic aortic valve replacement in patients less than or equal to
70 years of age. The numbers of patients at risk for each mismatch group are
reported.
The Journal of Thoracic and Cand 80 years. For patients less than or equal to 60 years of
age, PPM had a negative impact on survival (10-year sur-
vival: 25%  19% severe PPM, 26%  10% moderate
PPM, and 62%  13%, no PPM; P ¼ .03). However, for
patients greater than 60 years of age, survival was indepen-
dent of PPM (10-year survival: 41%  6% severe PPM,
33%  3% moderate PPM, and 32%  5%, no PPM;
P ¼ .73). For patients less than or equal to 80 years of
age, PPM had a negative impact on survival, but to a lesser
degree than with a 60 or 70 age cutoff (10-year survival:
40%  6% severe PPM, 37%  3% moderate PPM, and
42%  5%, no PPM; P ¼ .05). As expected, for patients
greater than 80 years of age, avoidance of PPM did not
improve survival (10-year survival: 34%  15% severe
PPM, 20%  5% moderate PPM, and 11%  7%, no
PPM; P ¼ .01). Looking specifically at patients in their
seventies (n ¼ 560), PPM did not affect survival (10-year
survival: 44%  7% severe PPM, 34%  4% moderate
PPM, and 39%  7%, no PPM; P ¼ .49).
To minimize the potential impact of obesity on the inci-
dence of PPM, we repeated the analyses replacing actual
body weight with ideal body weight using the height-based
formula of Devine as discussed by Pai and Paloucek.13 The
incidence of severe and moderate PPM fell only slightly
from 12% and 50% using actual body weight to 11% and
46% using ideal body weight. In addition, the impact of
PPM on late survival remained important in younger pa-
tients (P ¼ .04), but not in older patients (P ¼ .20).
Comment
Previous studies have demonstrated improved LV mass
regression with larger valves (increased EOA)9,14 and
a higher incidence of congestive heart failure and diminished
exercise capacity with smaller valves in young pa-
tients,3,15,16 but the impact of PPM on survival remains
FIGURE 5. Impact of prosthesis–patient mismatch (PPM) on late survival
after bioprosthetic aortic valve replacement in patients greater than 70 years
of age. The numbers of patients at risk for each mismatch group are reported.
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patients undergoing AVR for statistical analyses, making it
difficult to tease out the importance of mismatch in specific
patient subgroups. One of the early major studies to examine
the impact of PPM on survival was from the combined Tor-
onto and Vancouver groups.1 Rao and coauthors1 reviewed
2154 patients who underwent bioprosthetic AVR and re-
ported no difference in overall survival for the entire cohort,
either with mismatch, defined as EOA/BSA less than 0.75
cm2/m2, or without mismatch. They did notice, however,
a fall in freedom from valve-related death when mismatch
was present. One of the arguments tempering the importance
of their finding was verbalized by Eugene Blackstone during
the discussion of his paper presented at the 80th Annual
Meeting of The American Association for Thoracic Surgery
in Toronto when he reminded us that it generally does not
matter to patients whether they experience a valve-related
or non–valve-related death.6 In an elegant multicenter study,
Blackstone and colleagues6 used advanced statistical tech-
niques to demonstrate no impact on long-term survival
with PPM after AVR. More recent reports have performed
subgroup analyses to elucidate differences in survival with
PPM.8,9
Recent work from our center and from the Ottawa group
suggest that the magnitude to which varying degrees of PPM
affect early and late survival is not uniform and depends on
specific patient characteristics such as age, body size, and the
preoperative degree of LV dysfunction.8,9 Reul and associ-
ates9 from Ottawa monitored 805 patients prospectively
who underwent AVR between 1990 and 2003 and reported
decreased survival with PPM in patients with LV dysfunc-
tion, but not in those with normal LV function. Their series
included patients undergoing mechanical (54%), biopros-
thetic (39%), and homograft (7%) AVR. Preoperative LV
function was defined as normal (ejection fraction  50%)
in 548 patients versus impaired (ejection fraction< 50%)
in 257 patients. They found that PPM, defined as EOA/
BSA less than 0.85 cm2/m2, did not affect 10-year survival
or clinical symptoms in patients with normal LV function.
However, patients with PPM and LV dysfunction experi-
enced not only decreased late survival at 10 years, but also
a decline in freedom from heart failure symptoms and dimin-
ished LV mass regression compared with patients with LV
dysfunction but no PPM. They concluded that patients
with impaired LV function preoperatively represent a ‘‘criti-
cal population’’ in whom PPM should be avoided.
A previous report from our center noted that although
PPM was important for ‘‘average-sized’’ and ‘‘large’’ pa-
tients, PPM was not important for ‘‘small’’ patients.8 Our
earlier series examined 1400 patients undergoing mechani-
cal (467 patients, 33%) or bioprosthetic (933, 67%) AVR.
Patients were separated into 3 subgroups on the basis of
body size, including ‘‘small’’ (BSA<1.7 m2 in 20%), ‘‘av-
erage’’ (BSA between 1.7 and 2.1 m2 in 56%), and ‘‘large’’
(BSA>2.1 m2 in 24%). For small patients, PPM, defined as
EOA/BSA less than 0.75 cm2/m2, did not affect survival
with bioprosthetic or mechanical valves. For average-sized
patients, PPM was associated with impaired survival with
both bioprosthetic and mechanical valves. For large patients,
PPM was associated with impaired survival with mechanical
but not bioprosthetic valves. In the current report, PPM was
found to affect survival after bioprosthetic AVR in patients
younger than 70 years of age, but not patients older than
70 years of age. Combing the results of our two analyses,
one can conclude the following: (1) It is important to ensure
a favorable EOA/BSA ratio in younger patients undergoing
AVR, especially if they are average-sized or large, by either
considering a root-enlarging procedure17 or by implanting
a prosthesis with favorable flow characteristics, and (2)
PPM does not affect survival in older patients, especially
if they are small, such that a ‘‘get in and get out’’ approach
may be most appropriate in this patient subgroup.
Study Limitations
The current series included 1399 patients who underwent
bioprosthetic AVR by 22 different surgeons over a 15-year
period. Diversity in this series was immense, in both patient
selection and surgical approach. These data represent an un-
edited, full-disclosure report of patients undergoing biopros-
thetic AVR under all clinical circumstances—no patients
were excluded. Some may consider such diversity a limita-
tion to our ability to make conclusions on the basis of these
data, but we believe that this diversity not only strengthens
the findings, but also increases its applicability to the every-
day surgeon and everyday patient. Obviously, this series
involves a retrospective, nonrandomized comparison of sur-
gical results, including selection bias as to which patients
may have had their prostheses ‘‘upsized’’ to avoid mismatch
preemptively. Multivariate analysis was used to help ac-
count for selection bias and other confounding risk factors,
but selection bias can never be eliminated completely in a ret-
rospective review, regardless of the complexity of the statis-
tical manipulations used for such means. Finally, the current
report focused only on survival and did not address late func-
tional state, LV mass regression, or other clinical measures.
Unfortunately, postoperative echocardiographic imaging
was not consistent in our experience and follow-up was per-
formed many years after the procedure after many patients
had died.
In summary, the current report demonstrates that PPM is
an age-dependent phenomenon. PPM had a negative impact
on survival in young patients, but its impact in older patients
was minimal. For patients less than or equal to 70 years of
age, the surgical focus should be to ensure a favorable
EOA/BSA ratio and avoid PPM with all valves. For patients
greater than 70 years of age, PPM is not important for long-
term survival, such that a surgical approach that minimizes
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